clesrovimab-cfor (Enflonsia)

Indications

• passive immunity against respiratory syncytial virus (RSV)

Dosage

• 0.7 mL (150 MG/ML) Prefilled Syringe

Mechanism of action

• targets RSV fusion (F) protein
  • binds to a conserved epitope on the F protein
  • prevents RSV from fusing with & entering host cells

More general terms

• pharmaceutical monoclonal antibody